Specimen Transport
Articles & Testing Guides
Education
Outreach Resource Center
- Support Services
- Operations
- Sales and Marketing
- Billing and Finance
- Regulatory
- Examples
- More Resources
- Contact Outreach Team
| Web: | MayoMedicalLaboratories.com |
|---|---|
| Email: | mml@mayo.edu |
| Telephone: | 800.533.1710 |
| International: | 507.266.5700 |
| Values are valid only on day of printing. | |
Hunter syndrome (mucopolysaccharidosis II) results from a de-
ficiency of the iduronate sulfatase enzyme. This enzyme catalyzes
the removal of sulfate groups on the C-2 position of iduronic acid
residues of heparin, heparan sulfate, and dermatan sulfate.
In this procedure, the tritiated disulfated disaccharide,
O-(a-L-idopyranosyluronic acid 2-sulfate)-(1-4)-2,5-anhydro-D-
[3]H-mannitol-6-sulfate, is used as the substrate. The enzyme
hydrolyses the substrate to form inorganic sulfate and labeled
monosulfated disaccharide. The monosulfated product is then
separated from the disulfated substrate by anion exchange
chromatography. (Wasteson A, Neufeld EF: Iduronate sulfatase
from human plasma. Meth Enzymol 1982;83:573-578)

